Ravoxertinib

DB15281InvestigationalSmall molecule

Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 1 and Mitogen-activated protein kinase 3
Curator reviewed
Formula / weight: C₂₁H₁₈ClFN₆O₂ · 440.86 g/mol (avg)
Code names: GDC-0994

Resolves to

Compound

UNIIR6AXV96CRHCAS1453848-26-4ChEMBLCHEMBL3544964

Structure

InChIKeyRZUOCXOYPYGSKL-GOSISDBHSA-NSMILESCN1N=CC=C1NC1=NC=CC(=N1)C1=CC(=O)N(C=C1)[C@H](CO)C1=CC(F)=C(Cl)C=C1

Targets

P28482MAPK1P27361MAPK3

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ravoxertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account